^
Association details:
| Biomarker: | Chr t(11;14) |
|---|---|
| Cancer: | Multiple Myeloma |
| Drug Class: | BRAF inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Feasibility and Benefit of Molecularly-Informed Enrollment into Personalized Therapies or Early Phase Trials for Patients with Relapsed or Refractory Multiple Myeloma
Published date:
11/01/2018
Excerpt:
...8 (17%) pts with t(11;14) and 5 (11%) pts with BRAF V600E mutations. Eight (17%) out of the 46 pts were treated in molecularly oriented (MO) personalized therapies or eaCTs, and 38 (83%) pts were treated in non-MO therapies or eaCTs. The MO pts received BRAF inhibitor alone or in combination with MEK inhibitor (n=5), or BCL2 inhibitor given in combination with bortezomib and dexamethasone (n=3). The overall response rate was 75% (4 VGPR, 1 PR and 1 CR) in MO pts versus 11% (4 PR) in non-MO pts (p<0.0001).
DOI:
10.1182/blood-2018-99-111050
